Clinical Trial Update: Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating osimertinib in combination with chemotherapy for uncommon EGFR-mutant non-small cell lung cancer has been terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-15